Axsome Therapeutics, Inc (AXSM) Stock Quote & Options Analysis | Frenzy Capital
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $96.09 – $217.00
- YTD
- +15.45%
- IV Rank (30D)
- 35.59
- Straddle Price
- $15.55
- P/C Vol Ratio
- 0.92
- Market Cap
- $10.6B
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $10.6B
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +3.74% | 6 |
| Feb | -3.89% | 6 |
| Mar | +3.35% | 6 |
| Apr | +3.60% | 6 |
| May | -4.14% | 6 |
| Jun | +13.02% | 5 |
| Jul | -3.55% | 5 |
| Aug | +6.54% | 5 |
| Sep | -4.00% | 5 |
| Oct | +3.53% | 5 |
| Nov | +14.31% | 5 |
| Dec | +4.48% | 5 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 73.2 | Overbought |
| MACD | 7.442 | Bullish |
| SMA 50 | $171.71 | Above |
| SMA 200 | $147.56 | Above |
| Bollinger Bands | Overbought | |
| ADX | 28.9 | Trend |
| HV 30 | 47.2% |
LLM Stock Analysis Report
Executive Summary
This report presents an in-depth analysis of Axsome Therapeutics (AXSM). My overall assessment is NEUTRAL with a confidence level of 6/10.
Key drivers: The company's recent FDA acceptance and priority review of its supplemental new drug application for AXS-05, which treats Alzheimer's disease agitation, are positive catalysts. Additionally, the biotech industry's growth momentum and Axsome's pipeline developments support the stock's potential.
Primary risks: High IV rank (35.6%) indicates that volatility is relatively high, which could lead to increased price swings. The options market is pricing a significant move ($15.55 by expiration), highlighting the need for risk management strategies.
Investment thesis: AXSM presents an attractive entry point due to its strong fundamental story and recent news catalysts. However, caution should be exercised given the high IV rank and potential price volatility.
Recent news sentiment impact: The recent FDA acceptance and priority review of AXS-05 have positively impacted the stock's news sentiment, with all five recent headlines showing positive or neutral sentiments.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): NEUTRAL; Medium-term (1-3 months): BULLISH; Long-term (3-12 months): NEUTRAL
Support/Resistance Levels:
- Lower: $165.39 (Bollinger Bands' lower band)
- Middle: $184.30 (SMA 50)
- Upper: $203.21 (Bollinger Bands' upper band)
Momentum Signals:
- RSI interpretation: Overbought (>70), with a value of 73.21
- MACD signal: Bullish, with a histogram value of 5.61
- Bollinger Bands position: Squeeze
Volume Analysis: Volume trends indicate institutional interest, with an OBV value of 12372008.30 and a volume rate of change (VROC) of 113.13%.
News & Sentiment Analysis
Recent Headlines Summary: The headlines highlight the company's recent FDA acceptance and priority review of AXS-05, as well as positive industry trends and analyst recommendations.
Sentiment Assessment: Aggregate news sentiment is POSITIVE, with a majority of headlines showcasing optimistic views on the biotech sector and Axsome's pipeline developments.
Catalyst Identification: The upcoming earnings report (May 4) may be a catalyst for price movements.
Market Narrative: The recent FDA acceptance and priority review of AXS-05 aligns with the technical signals, suggesting continued upward momentum in the short term.
Risk & Volatility Assessment
Beta Interpretation: Beta is relatively low at 0.69, indicating that the stock moves less than the broader market (SPY).
Volatility Regime: Current volatility is high, with an IV rank of 35.6% and a current IV value of 80.3%.
Options Market Signals: The options market is pricing a significant move ($15.55 by expiration), indicating high volatility.
Downside Protection: Support levels at $165.39 (Bollinger Bands' lower band) and $171.71 (SMA 50) should be monitored for potential downside risk management considerations.
Market Context & Positioning
Sector Performance: The biotech sector has been trending upward, supporting Axsome's stock price.
Institutional Activity: Institutional interest is evident through the OBV value of 12372008.30 and the volume rate of change (VROC) of 113.13%.
Correlation Analysis: Correlation with SPY is low at 0.21, indicating that AXSM has a relatively independent price movement.
Relative Valuation: Axsome's stock price is positioned within its trading range, making it an attractive entry point for long-term investors.
Key Levels & Action Items
Critical Price Levels:
- Support: $165.39 (Bollinger Bands' lower band) and $171.71 (SMA 50)
- Resistance: $203.21 (Bollinger Bands' upper band)
Breakout/Breakdown Levels: Technical levels that could trigger significant moves include the SMAs (20, 50, and 200) and the Bollinger Bands.
Time-Sensitive Catalysts: The upcoming earnings report (May 4) may be a catalyst for price movements.
Risk Management: Stop-loss levels should be set at $165.39 (Bollinger Bands' lower band) to manage potential downside risk, with position sizing considerations guided by the options market's pricing of a significant move ($15.55 by expiration).
| Published | Title | Publisher | Sentiment |
|---|---|---|---|
| 2026-05-04 | Hypercharge Grows Total Charging Ports by over 45% Through Acquisition of Eddie from AXSO | Benzinga | |
| 2026-04-08 | Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4 | GlobeNewswire Inc. | |
| 2026-03-25 | Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now | The Motley Fool | |
| 2026-02-26 | Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders | Benzinga | |
| 2026-01-08 | Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out | Investing.com | |
| 2026-01-08 | 2 Healthcare Stocks to Buy for 2026 and Beyond | The Motley Fool | |
| 2025-12-31 | Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation | GlobeNewswire Inc. | |
| 2025-12-02 | 2 Under-the-Radar Stocks to Buy Heading Into 2026 | The Motley Fool |
- IV Rank (30D)
- 35.59
- IV Rank (7D)
- 35.59
- Avg IV
- 80.3%
- Straddle (30D)
- $15.55
- Straddle (7D)
- $15.55
- P/C Volume
- 0.92
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 0.69
- Correlation (SPY)
- 20.9%
- R²
- 0.04
- Ann. Volatility
- 41.1%
- SPY Volatility
- 12.5%
Low volatility - stock moves less than market
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 107.8 |
| P/S Ratio | 14.9 |
| EV/EBITDA | -58.7 |
| ROE | -207.5% |
| Debt/Equity | 2.17 |